Skip to main content

Advertisement

Log in

SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

Colorectal liver metastases (CLM) have significant molecular heterogeneity, which contributes to the risk of recurrence following surgery. Most of the traditional scores intended to predict recurrence is based on clinicopathological variables and it is unclear whether incorporating molecular biomarkers might improve our assessment of the risk of recurrence. Our aim was to determine if molecular biomarkers might be associated with the risk of recurrence after surgery of CLM.

Patients and methods

A total of 121 patients diagnosed with colorectal cancer (CRC) with resected liver metastases were included. The role of several clinicopathological variables to predict patient’s outcome after resection of liver metastases was analyzed. Eighteen genes related to CRC pathogenesis were also included in the analyses. Univariate and multivariate stepwise Cox regression analyses were performed to identify factors associated with recurrence and the risk of death.

Results

Eight prognostic factors for progression-free survival and nine factors for overall survival were identified in the univariate analyses. After adjusting for other risk factors, only the expression of two molecular factors was associated with the risk of recurrence: TS (HR 0.631, 95 % CI 0.422–0.944) and SMAD4 (HR 1.680, 95 % CI 1.047–2.695). None of the variables was significantly associated with the risk of death in the multivariate analyses.

Conclusions

The prognostic significance of most traditional clinicopathological variables might be insufficient to define patients at risk for recurrence after liver metastases resection. Molecular biomarkers might improve the identification of patients with higher risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.

    Article  PubMed  Google Scholar 

  2. Rees M, Tekkis PP, Welsh FKS, Welsh FK, O’Rourke T, John TG. Evaluation of long term survival after hepatic resection for metastatic colorectal cancer. A multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.

    Article  PubMed  Google Scholar 

  3. Figueras J, Valls C, Rafecas A, Fabregat J, Ramos E, Jaurrieta E. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg. 2001;88(7):980–5.

    Article  CAS  PubMed  Google Scholar 

  4. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000;7:643–50.

    Article  CAS  PubMed  Google Scholar 

  5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.

    Article  CAS  PubMed  Google Scholar 

  6. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg. 2001;25:638–44.

    Article  CAS  PubMed  Google Scholar 

  7. Malik HZ, Prasad R, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246:806–14.

    Article  PubMed  Google Scholar 

  8. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60. doi:10.1056/NEJMra0804588.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Mejia A, Schulz S, Hyslop T, Weinberg DS, Walkman SAJ. Molecular staging individualizing cancer management. Surg Oncol. 2012;105(5):468–74. doi:10.1002/jso.21858.

    Article  CAS  Google Scholar 

  10. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology. 1998;55(6):575–81.

    Article  CAS  PubMed  Google Scholar 

  11. Tokunaga T, Nakamura M, Oshika Y, Abe Y, Ozeki Y, Fukushima Y, et al. Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer. Br J Cancer. 1999;79(2):354–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF, et al. p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol. 1996;14(10):2696–701.

    CAS  PubMed  Google Scholar 

  13. Dômont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, et al. Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol. 2005;23(13):3086–93.

    Article  PubMed  Google Scholar 

  14. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. EJSO. 2001;27(1):80–7.

    Article  CAS  PubMed  Google Scholar 

  15. Laird A, O’Mahony FC, Nanda J. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One. 2013;8(4):e60483. doi:10.1371/journal.pone.0060483.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Gerlinger Marco, Rowan AJ. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. NEJM. 2012;366(10):883–92.

    Article  CAS  PubMed  Google Scholar 

  17. Boulay JL, Mild G, Lowy A, Reuter J. SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. Br J Cancer. 2002;87(6):630–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Yamane T, Seshimo A, Kameoka S. Analysis of the mRNA expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyl transferase (OPRT) in liver metastases from colorectal cancer. Hepatogastroenterology. 2012;60(122):291–5.

    Google Scholar 

  19. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8(10):898–911.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

All authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. López-Gómez.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

López-Gómez, M., Moreno-Rubio, J., Suárez-García, I. et al. SMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases. Clin Transl Oncol 17, 133–138 (2015). https://doi.org/10.1007/s12094-014-1202-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1202-x

Keywords

Navigation